High-density Lipoprotein (HDL) As an Indicator for Alcohol Use in a Psychiatrically Ill Population

Overview

Journal Alcohol Alcohol

Publisher Oxford University Press

Specialty Psychiatry

Date 2024 Apr 28

PMID 38678370

Authors

Nicole M Benson

Amin Yakubu

Boyu Ren

Carol Aboud

Victoria Vargas

Shelly F Greenfield

Alisa B Busch

Affiliations

Soon will be listed here.

Abstract

Aims: To examine the cross sectional and longitudinal associations between the Alcohol Use Disorders Identification Test-Concise (AUDIT-C) and differences in high-density lipoprotein (HDL) in a psychiatrically ill population.

Methods: Retrospective observational study using electronic health record data from a large healthcare system, of patients hospitalized for a mental health/substance use disorder (MH/SUD) from 1 July 2016 to 31 May 2023, who had a proximal AUDIT-C and HDL (N = 15 915) and the subset who had a repeat AUDIT-C and HDL 1 year later (N = 2915). Linear regression models examined the association between cross-sectional and longitudinal AUDIT-C scores and HDL, adjusting for demographic and clinical characteristics that affect HDL.

Results: Compared with AUDIT-C score = 0, HDL was higher among patients with greater AUDIT-C severity (e.g. moderate AUDIT-C score = 8.70[7.65, 9.75] mg/dl; severe AUDIT-C score = 13.02 [12.13, 13.90] mg/dL[95% confidence interval (CI)] mg/dl). The associations between cross-sectional HDL and AUDIT-C scores were similar with and without adjusting for patient demographic and clinical characteristics. HDL levels increased for patients with mild alcohol use at baseline and moderate or severe alcohol use at follow-up (15.06[2.77, 27.69] and 19.58[2.77, 36.39] mg/dL[95%CI] increase for moderate and severe, respectively).

Conclusions: HDL levels correlate with AUDIT-C scores among patients with MH/SUD. Longitudinally, there were some (but not consistent) increases in HDL associated with increases in AUDIT-C. The increases were within range of typical year-to-year variation in HDL across the population independent of alcohol use, limiting the ability to use HDL as a longitudinal clinical indicator for alcohol use in routine care.

References

Saunders J, Aasland O, Babor T, De la Fuente J, Grant M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993; 88(6):791-804. DOI: 10.1111/j.1360-0443.1993.tb02093.x. View

Bush K, Kivlahan D, McDonell M, Fihn S, Bradley K . The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998; 158(16):1789-95. DOI: 10.1001/archinte.158.16.1789. View

Wallace R, Hunninghake D, Reiland S, Barrett-Connor E, Mackenthun A, Hoover J . Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications. The Lipid Research Clinics Program Prevalence Study. Circulation. 1980; 62(4 Pt 2):IV77-82. View

Hartgens F, Rietjens G, Keizer H, Kuipers H, Wolffenbuttel B . Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004; 38(3):253-9. PMC: 1724824. DOI: 10.1136/bjsm.2003.000199. View

Henderson D, Vincenzi B, Andrea N, Ulloa M, Copeland P . Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015; 2(5):452-464. DOI: 10.1016/S2215-0366(15)00115-7. View

Zema M . Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol. 2000; 35(3):640-6. DOI: 10.1016/s0735-1097(99)00585-9. View

Rubinow K, Vaisar T, Tang C, Matsumoto A, Heinecke J, Page S . Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res. 2012; 53(7):1376-83. PMC: 3371249. DOI: 10.1194/jlr.P026005. View

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 73(24):e285-e350. DOI: 10.1016/j.jacc.2018.11.003. View

Williams E, Fletcher O, Frost M, Harris A, Washington D, Hoggatt K . Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration. JAMA Netw Open. 2022; 5(6):e2219651. PMC: 9247731. DOI: 10.1001/jamanetworkopen.2022.19651. View

10.

Lee S, Humphreys K, Flory K, Liu R, Glass K . Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011; 31(3):328-41. PMC: 3180912. DOI: 10.1016/j.cpr.2011.01.006. View

11.

Pereira M, Weggemans R, Jacobs Jr D, Hannan P, Zock P, Ordovas J . Within-person variation in serum lipids: implications for clinical trials. Int J Epidemiol. 2004; 33(3):534-41. DOI: 10.1093/ije/dyh057. View

12.

Kasiske B, Ma J, Kalil R, Louis T . Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995; 122(2):133-41. DOI: 10.7326/0003-4819-122-2-199501150-00010. View

13.

Henkin Y, Como J, Oberman A . Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA. 1992; 267(7):961-8. DOI: 10.1001/jama.267.7.961. View

14.

Birjmohun R, Hovingh G, Stroes E, Hofstra J, Dallinga-Thie G, Meijers J . Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clin Ther. 2009; 30(12):2314-23. DOI: 10.1016/j.clinthera.2008.12.021. View

15.

Charach A, Yeung E, Climans T, Lillie E . Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2010; 50(1):9-21. DOI: 10.1016/j.jaac.2010.09.019. View

16.

Berger D, Williams E, Bryson C, Rubinsky A, Bradley K . Alcohol questionnaires and HDL: screening scores as scaled markers of alcohol consumption. Alcohol. 2013; 47(6):439-45. DOI: 10.1016/j.alcohol.2013.07.001. View

17.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B . Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003; 64(5):598-604. DOI: 10.4088/jcp.v64n0516. View

18.

Bradley K, Rubinsky A, Lapham G, Berger D, Bryson C, Achtmeyer C . Predictive validity of clinical AUDIT-C alcohol screening scores and changes in scores for three objective alcohol-related outcomes in a Veterans Affairs population. Addiction. 2016; 111(11):1975-1984. DOI: 10.1111/add.13505. View

19.

Filakovic P, Eric A, Radanovic-Grguric L . Metabolic syndrome and psychotropic medications. Med Glas (Zenica). 2012; 9(2):180-8. View

20.

Wofford M, King D, Harrell T . Drug-induced metabolic syndrome. J Clin Hypertens (Greenwich). 2006; 8(2):114-9. PMC: 8109499. DOI: 10.1111/j.1524-6175.2006.04751.x. View